The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis

Parreira, Natállia A.; Ramalho, Fernando Silva; Augusto, Matheus Ribeiro; Silva, Deisy Mara; Prado, Cibele M.; Júnior, Jorge Elias; Rodrigues, Vanderlei; Ramalho, Leandra Naíra Zambelli

doi:10.1016/j.exppara.2018.05.004

Cited by 5 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But enalapril caused an insignificant reduction. In S. mansoniinfected mice, there was a decrease in the protein production of TGFβ1, the main factor used by angiotensin II for the activation of HSC in animals treated with losartan (Parreira et al, 2018).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Blocking angiotensin pathway induces anti-fibrotic effects in a mouse model of schistosomiasis by decreasing egg burden and granulomatous reaction

El-Barabry

Habbak

Mansour

et al. 2021

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

It is with great pleasure that I write this editorial to welcome you to the IJCBR. This journal provides a platform for publication of original and reviews research articles, short communications, letter to editor, thesis abstract, conference report, and case studies. These types of publication are directed at the interface of the fields of cancer and biomedical research.The IJCBR relies on a distinguished expert of the Advisory and Editorial Board Members from the top international league covering in depth the related topics. They timely review all manuscripts and maintain highest standards of quality and scientific methodology and ethical concepts. Meanwhile, we take all possible means to keep the time of the publication process as short as possible.I take this chance to welcome your contributions to the IJCBR and have every expectation that it will soon become one of the most respected journals in both the fields of cancer and biomedical research.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Losartan is an angiotensin II type 1 receptor (AT1) antagonist and enalapril is an angiotensinconverting enzyme (ACE) inhibitor. Both have been shown to reduce hepatic fibrosis caused by various aetiologies (El-Lakkany et al, 2011;Attia et al, 2013;Parreira et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Blocking angiotensin pathway induces anti-fibrotic effects in a mouse model of schistosomiasis by decreasing egg burden and granulomatous reaction

El-Barabry

Habbak

Mansour

et al. 2021

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

show abstract

“…The therapeutic properties of BK on schistosomal hepatic fibrosis were analyzed in schistosoma cercariae-inoculated mice. The authors demonstrated a reduction of hepatic fibrosis in BK-treated groups, via RAS blockage, with decreased collagen deposition and TGFβ1 protein expression [ 185 ]. The role of kinin system in parasite infections is illustrated in Figure 3 .…”

Section: Kinins and Their Implication In Protozoan And Parasite Inmentioning

confidence: 99%

Kinins and Their Receptors in Infectious Diseases

2020

View full text Add to dashboard Cite

Kinins and their receptors have been implicated in a series of pathological alterations, representing attractive pharmacological targets for several diseases. The present review article aims to discuss the role of the kinin system in infectious diseases. Literature data provides compelling evidence about the participation of kinins in infections caused by diverse agents, including viral, bacterial, fungal, protozoan, and helminth-related ills. It is tempting to propose that modulation of kinin actions and production might be an adjuvant strategy for management of infection-related complications.

show abstract

“…Regarding treatment of schistosomiasis-associated liver fibrosis with chemical drugs, the function of renin-angiotensin system (RAS) inhibitors and kaempferol in alleviating hepatic fibrosis have been extensively studied. These drugs can inhibit HSC activation and reduce collagen and TGF-β production [107, 108]. Both taurine supplementation and combining PZQ with silymarin substantially ameliorate liver fibrosis, likely by downregulating relevant cytokines or chemokines and reducing the endoplasmic reticular stress response [109, 110].…”

Section: Use Of Mirnas To Treat Schistosomiasis-associated Hepatic Fimentioning

confidence: 99%

The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis

et al. 2019

View full text Add to dashboard Cite

Schistosomiasis is a prevalent parasitic disease worldwide. The main pathological changes of hepatosplenic schistosomiasis are hepatic granuloma and fibrosis due to worm eggs. Portal hypertension and ascites induced by hepatic fibrosis are usually the main causes of death in patients with chronic hepatosplenic schistosomiasis. Currently, no effective vaccine exists for preventing schistosome infections. For quite a long time, praziquantel (PZQ) was widely used for the treatment of schistosomiasis and has shown benefit in treating liver fibrosis. However, drug resistance and chemical toxicity from PZQ are being increasingly reported in recent years; therefore, new and effective strategies for treating schistosomiasis-induced hepatic fibrosis are urgently needed. MicroRNA (miRNA), a non-coding RNA, has been proved to be associated with the development of many human diseases, including schistosomiasis. In this review, we present a balanced and comprehensive view of the role of miRNAs in the pathogenesis, grading, and treatment of schistosomiasis-associated hepatic fibrosis. The multiple regulatory roles of miRNAs, such as promoting or inhibiting the development of liver pathology in murine schistosomiasis are also discussed in depth. Additionally, miRNAs may serve as candidate biomarkers for diagnosing liver pathology of schistosomiasis and as novel therapeutic targets for treating schistosomiasis-associated hepatic fibrosis.

show abstract

The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis

Cited by 5 publications

References 44 publications

Blocking angiotensin pathway induces anti-fibrotic effects in a mouse model of schistosomiasis by decreasing egg burden and granulomatous reaction

Blocking angiotensin pathway induces anti-fibrotic effects in a mouse model of schistosomiasis by decreasing egg burden and granulomatous reaction

Kinins and Their Receptors in Infectious Diseases

The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis

Contact Info

Product

Resources

About